179 related articles for article (PubMed ID: 16874005)
1. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.
Kato M; Fukuda T; Wakeno M; Fukuda K; Okugawa G; Ikenaga Y; Yamashita M; Takekita Y; Nobuhara K; Azuma J; Kinoshita T
Neuropsychobiology; 2006; 53(4):186-95. PubMed ID: 16874005
[TBL] [Abstract][Full Text] [Related]
2. 5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial.
Kato M; Nonen S; Serretti A; Tetsuo S; Takekita Y; Azuma J; Kinoshita T
J Clin Psychopharmacol; 2013 Feb; 33(1):131-2. PubMed ID: 23288236
[No Abstract] [Full Text] [Related]
3. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.
Murata Y; Kobayashi D; Imuta N; Haraguchi K; Ieiri I; Nishimura R; Koyama S; Mine K
J Clin Psychopharmacol; 2010 Feb; 30(1):11-7. PubMed ID: 20075642
[TBL] [Abstract][Full Text] [Related]
4. Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
Inoue T; Honda M; Kawamura K; Tsuchiya K; Suzuki T; Ito K; Matsubara R; Shinohara K; Ishikane T; Sasaki K; Boku S; Fujisawa D; Ono Y; Koyama T
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):223-7. PubMed ID: 22504727
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients.
Suzuki Y; Sawamura K; Someya T
Neuropsychopharmacology; 2006 Apr; 31(4):825-31. PubMed ID: 16205777
[TBL] [Abstract][Full Text] [Related]
6. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
[TBL] [Abstract][Full Text] [Related]
7. Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression.
Morishita S; Arita S
Hum Psychopharmacol; 2003 Aug; 18(6):479-82. PubMed ID: 12923828
[TBL] [Abstract][Full Text] [Related]
8. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
[TBL] [Abstract][Full Text] [Related]
9. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.
Serretti A; Cusin C; Rossini D; Artioli P; Dotoli D; Zanardi R
Am J Med Genet B Neuropsychiatr Genet; 2004 Aug; 129B(1):36-40. PubMed ID: 15274037
[TBL] [Abstract][Full Text] [Related]
10. Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.
Lohoff FW; Aquino TD; Narasimhan S; Multani PK; Etemad B; Rickels K
Pharmacogenomics J; 2013 Feb; 13(1):21-6. PubMed ID: 22006095
[TBL] [Abstract][Full Text] [Related]
11. Paroxetine versus placebo: a double-blind comparison in depressed patients.
Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC
J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
[TBL] [Abstract][Full Text] [Related]
12. Interaction between SERTPR and stressful life events on response to antidepressant treatment.
Mandelli L; Marino E; Pirovano A; Calati R; Zanardi R; Colombo C; Serretti A
Eur Neuropsychopharmacol; 2009 Jan; 19(1):64-7. PubMed ID: 18815011
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine.
Reimherr F; Amsterdam J; Dunner D; Adler L; Zhang S; Williams D; Marchant B; Michelson D; Nierenberg A; Schatzberg A; Feldman P
Psychiatry Res; 2010 Jan; 175(1-2):67-73. PubMed ID: 19969374
[TBL] [Abstract][Full Text] [Related]
14. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
Kiev A; Feiger A
J Clin Psychiatry; 1997 Apr; 58(4):146-52. PubMed ID: 9164424
[TBL] [Abstract][Full Text] [Related]
15. Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene.
Perna G; Favaron E; Di Bella D; Bussi R; Bellodi L
Neuropsychopharmacology; 2005 Dec; 30(12):2230-5. PubMed ID: 16034444
[TBL] [Abstract][Full Text] [Related]
16. Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression.
Zanardi R; Magri L; Rossini D; Malaguti A; Giordani S; Lorenzi C; Pirovano A; Smeraldi E; Lucca A
Eur Neuropsychopharmacol; 2007 Oct; 17(10):651-7. PubMed ID: 17466494
[TBL] [Abstract][Full Text] [Related]
17. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.
Kato M; Serretti A; Nonen S; Takekita Y; Wakeno M; Azuma J; Kinoshita T
Transl Psychiatry; 2015 Feb; 5(2):e513. PubMed ID: 25710119
[TBL] [Abstract][Full Text] [Related]
18. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder.
Lin E; Chen PS; Chang HH; Gean PW; Tsai HC; Yang YK; Lu RB
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1167-72. PubMed ID: 19560507
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
Kato M; Wakeno M; Okugawa G; Fukuda T; Takekita Y; Hosoi Y; Azuma J; Kinoshita T; Serretti A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1041-4. PubMed ID: 18325652
[TBL] [Abstract][Full Text] [Related]
20. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder.
Sato K; Yoshida K; Takahashi H; Ito K; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K; Otani K
Neuropsychobiology; 2002; 46(3):136-40. PubMed ID: 12422060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
